Effectiveness of Glucocorticoids in Acute Respiratory Distress Syndrome: An Umbrella Review

Table 2

Description of included studies.

Author	Year	Design/participant (N)	Quality score	Primary outcome	Main findings
Meduri et al. [15]	2018	9 RCTs (N = 766)	7	Mortality	Glucocorticoid revealed mortality reduction for ARDS (RR = 0.68, 95% CI 0.57 to 0.82)
Yang et al. [22]	2017	14 RCTs (N = 772)	8	Mortality	Subgroup analysis of low- and high-dose glucocorticoid revealed mortality reduction (RR = 68, 95% CI 0.50 to 0.91)
Meduri et al. [17]	2016	8 RCTs (N = 569)	5	Weaning	Glucocorticoids reduce MV free days
Horita et al. [18]	2015	11 RCTs (N = 949)	9	Mortality	Glucocorticoid did not show significant difference on mortality reduction (RR = 0.77, 0.58 to 1.03)
Ruan et al. [21]	2014	8 RCTS and 10 cohort (N = 1474)	9	Mortality	Subgroup analysis did not show significant difference in mortality (RR = 1.14, 95% CI 0.79 to 1.65)
Khilnani and Hadda [19]	2011	9 RCTs (N = 1025)	5	Mortality	Glucocorticoid failed to show significant difference in mortality
Marik et al. [29]	2011	8 RCTs (N = 567)	3	Mortality	Glucocorticoid revealed mortality reduction for ARDS (RR = 0.68, 95% CI 0.56 to 0.81)
Sessler and Gay [23]	2010	4 RCTs and 5 cohort (N = 648)	3	Mortality	Subgroup analysis showed glucocorticoid mortality reduction (RR = 0.62, 95% CI 0.43 to 0.91)
Tang et al. [16]	2009	4 RCTs and 5 cohort (N = 648)	6	Mortality	Subgroup analysis showed glucocorticoid mortality reduction (RR = 0.62, 95% CI 0.43 to 0.91)
Peter et al. [20]	2008	9 RCTs (1073)	8	Mortality	Preventive steroid did not show significant benefit (OR = 1.55, 95% CI 0.58 to 4.05)

RCTs: randomized controlled trials; CI: confidence interval; RR: relative risk; OR: odds ratio.